AstraZeneca has acquired Modella AI, a life sciences–focused artificial intelligence company, in a move that deepens the companies’ existing collaboration and strengthens AstraZeneca’s use of advanced AI technologies across its global oncology portfolio. The acquisition builds on a multi-year agreement announced in July 2025 and reflects the pharmaceutical group’s strategy to embed data-driven innovation more deeply into drug discovery and clinical development. Financial terms of the transaction were not disclosed.
Under the expanded relationship, Modella AI’s generative and agentic AI platform will be integrated into AstraZeneca’s oncology research and development organization. The technology is designed to support multiple stages of the R&D process, including accelerating clinical development timelines, enhancing biomarker discovery, and enabling more sophisticated, data-driven decision-making across the oncology pipeline.
As cancer research becomes increasingly complex and data-intensive, pharmaceutical companies are turning to advanced AI tools to manage and interpret large volumes of clinical, molecular, and pathology data. Modella AI was built at the intersection of pathology, clinical datasets, and cutting-edge generative AI, with the goal of addressing some of the most challenging problems in oncology. Its multi-modal foundation models and AI agents are intended to generate deeper biological and clinical insights while improving automation, scalability, and consistency across research workflows.
Executives from Modella AI said the acquisition will allow their technology to be deployed at greater scale and with real-world impact. Company leaders noted that oncology drug development today requires AI solutions that are not only powerful but also practical and deployable in global trials and clinical settings. By joining AstraZeneca, Modella AI’s platform can be applied across a broad and diverse oncology pipeline, potentially accelerating development and improving outcomes for patients with cancer.
AstraZeneca executives highlighted the strategic value of the acquisition in advancing the company’s transformation of drug discovery and clinical development through AI. The addition of Modella AI’s frontier pathology foundation models and AI agents is expected to support the development of more targeted therapeutics and companion diagnostics within the oncology portfolio.
By embedding Modella AI’s capabilities directly into its research ecosystem, AstraZeneca aims to unlock new biological and clinical insights and further streamline data-intensive processes. The acquisition underscores AstraZeneca’s commitment to leveraging advanced artificial intelligence as a core component of its oncology innovation strategy.